Showing results (701-710 of 709) with videos related to
Sort By:
Pageof 71
You have reached the last page of results.This site can display upto 709 results.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.Hepatology (Baltimore, Md.)|February 2, 2026
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Jinyoung Byun, Caitlin J VanLith, et al.Lancet (London, England)|April 13, 2026
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort studyIsabel Graupera, Maja Thiele, Laurent Castera, et al.JHEP Reports : Innovation in Hepatology|March 1, 2021
Assessing the impact of COVID-19 on liver cancer management (CERO-19)Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.Pageof 71